Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3060 PEGASUS PARK DRIVE, BUILDING 6 DALLAS TX 75247 |
Tel: | N/A |
Website: | https://www.fortebiorx.com/home/default.aspx |
IR: | See website |
Key People | ||
Paul A. Wagner Chairman of the Board, Chief Executive Officer | Hubert C. Chen President, Chief Scientific Officer | Antony A. Riley Chief Financial Officer |
Business Overview |
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company's FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company's subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd. |
Financial Overview |
For the fiscal year ended 31 December 2023, Forte Biosciences Inc revenues was not reported. Net loss increased from $13.9M to $31.5M. Higher net loss reflects Research and development - Balancing val increase from $4.3M to $20.7M (expense), General and administrative - Balancing increase of 54% to $8.5M (expense), Other income (expenses) decrease from $17K (income) to $114K (expense). |
Employees: | 9 as of Mar 11, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$32.48M as of Dec 31, 2023 |
Net annual income (TTM): | -$31.48M as of Dec 31, 2023 |
Free cash flow (TTM): | -$28.72M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 36,394,882 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |